NASDAQ$ZLAB
Zai Lab Limited-ADR · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported solid financial results for the first quarter of 2022, driven by commercial growth and pipeline advancement.
Zai Lab reported total revenues of $46.7 million for the first quarter of 2022, compared to $20.1 million for the same period in 2021. The net loss was $82.4 million, compared to $232.9 million for the same period in 2021. The company continues to advance its pipeline and commercial operations.
- Total revenues reached $46.7 million, a significant increase from $20.1 million in the same period last year.
- Product revenues increased for ZEJULA, Optune, QINLOCK and NUZYRA.
- R&D expenses decreased due to no upfront payments for new licensing agreements.
- Zai Lab continues to progress toward achieving strategic priorities, including filing the NDA for efgartigimod in China in mid-2022.
Headline financials
Revenue & EPS history
Zai Lab · Revenue · Quarterly
$46.7M
Revenue by segment
Zai Lab · $30.3M total across 2 segments · Q1 2022
- ZEJULA$29.6M+134.9%97.7%
- NUZYRA$700K—2.3%
Forward guidance
Zai Lab anticipates several milestones in 2022, including regulatory submissions, clinical trial initiations, and data readouts for its key programs.
Tailwinds
- Filing the NDA for efgartigimod in China in mid-2022.
- Initiation of a registrational study for bemarituzumab in first-line gastric cancer in Greater China.
- Topline data readout for KarXT from its Phase 3 EMERGENT-2 trial in the third quarter of 2022.
- Continued investment in R&D to advance our proprietary pipeline with global rights, including moving ZL-1102 into full global development.
- Seek National Reimbursement Drug List (NRDL) inclusion for CABP and ABSSSI indications.
Headwinds
- Challenges due to the COVID situation in certain regions in China.
- Current macro and geopolitical headwinds.
- Uncertainties and risks associated with drug development and commercialization.
- Potential delays in regulatory approvals.
- The company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in its forward-looking statements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.1%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-0.5%
Avg return
30 days after
45%
13 / 29 earnings
Positive
+26.0%
Q1 2024
Best reaction
-11.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.9% | -7.0% | -20.9% | |
| Q4 2025 | +1.7% | -8.6% | -7.2% | |
| Q3 2025 | -6.4% | -11.3% | -21.4% | |
| Q1 2025 | +2.5% | +0.9% | +34.4% | |
| Q4 2024 | -2.0% | -3.1% | +6.3% | |
| Q3 2024 | -3.7% | -13.0% | -14.1% | |
| Q2 2024 | -5.6% | -7.8% | +11.3% | |
| Q1 2024 | +26.0% | +29.0% | +19.9% | |
| Q4 2023 | -0.9% | +0.5% | -23.7% | |
| Q3 2023 | +7.4% | +0.9% | -1.5% | |
| Q2 2023 | -11.2% | -5.4% | +3.5% | |
| Q1 2023 | +1.4% | -9.3% | -24.2% | |
| Q4 2022 | -0.6% | +7.3% | -10.5% | |
| Q3 2022 | +1.9% | +23.9% | +18.7% | |
| Q2 2022 | -5.0% | -6.2% | -8.0% | |
| Q1 2022 | -2.1% | +30.0% | +5.6% | |
| Q4 2021 | -4.0% | -26.0% | -19.6% | |
| Q3 2021 | +0.7% | -2.3% | -22.3% | |
| Q2 2021 | +0.6% | +0.9% | +0.4% | |
| Q1 2021 | -5.1% | -3.3% | +8.3% | |
| Q4 2020 | +0.3% | -7.0% | -9.6% | |
| Q4 2019 | -1.4% | -2.7% | +17.0% | |
| Q1 2020 | -8.7% | +3.1% | +18.3% | |
| Q2 2019 | +4.3% | +4.1% | -4.0% | |
| Q1 2019 | +3.7% | +6.7% | -9.7% | |
| Q4 2018 | +10.4% | +10.4% | +1.6% | |
| Q3 2018 | +6.7% | +13.6% | +13.1% | |
| Q4 2017 | -5.3% | -8.8% | +22.8% | |
| Q3 2017 | -2.2% | -0.6% | +0.3% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro